Altido Therapeutics
Altido Therapeutics is a clinical-stage biotechnology company developing CAR-TEAM, an autologous T cell-based immunotherapy platform designed to treat difficult solid tumors, starting with glioblastoma. Its lead candidate, ALTX-100, combines CAR-T cells with secreted bispecific T-cell-engaging molecules to target two tumor antigens simultaneously and is delivered directly into the cerebrospinal fluid to bypass the blood-brain barrier.
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
Funding
Founders
Product
Problem
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults, progressing quickly and resisting standard treatments, with fewer than 7% of patients surviving five years post-diagnosis. No therapy has meaningfully extended survival for patients whose disease returns after initial treatment, and conventional cell therapies have been ineffective against solid tumors due to heterogeneity, antigen escape, and T cell exhaustion.
Solution
Altido Therapeutics offers CAR-TEAM, a dual-mechanism immunotherapy platform engineered to overcome barriers that have limited cell therapies in solid tumors. Each dose uses a patient's own T cells, genetically modified to express a chimeric antigen receptor (CAR) targeting one tumor antigen while simultaneously secreting bispecific T-cell-engaging antibody molecules (TEAMs) that direct both CAR-T and bystander T cells against a second antigen. This two-pronged attack addresses tumor heterogeneity and antigen escape, while the design aims to reduce T cell exhaustion. The lead program, ALTX-100, targets EGFRvIII and EGFR in glioblastoma and is administered intraventricularly—directly into the cerebrospinal fluid—to bypass the blood-brain barrier and concentrate therapy at the tumor site.
Target Audience
Primary customers are patients with glioblastoma and other drug-resistant solid tumors, along with the oncologists and clinical institutions that treat them, as the company advances its clinical-stage programs through development and potential commercialization.
Features
- CAR-TEAM platform combining CAR-T cell therapy with bispecific T-cell-engaging antibody secretion in a single autologous product
- Dual antigen targeting: CARs bind EGFRvIII (a mutation found almost exclusively on cancer cells) while secreted TEAMs recruit immune cells against EGFR (expressed on most GBM tumors)
- Intraventricular delivery directly into cerebrospinal fluid to circumvent the blood-brain barrier
- Mechanism designed to counter key solid-tumor resistance factors including heterogeneity, antigen escape, and T cell exhaustion
- Lead candidate ALTX-100 is currently in clinical development for glioblastoma